Description
Grastim Solution for Injections 0.3 mg/ml – 1ml Syringe
Composition
Grastim Solution for Injections contains 0.3 mg/ml of the active ingredient, a granulocyte colony-stimulating factor (G-CSF) analog, essential for stimulating white blood cell production in the body.
Mechanism of Action
Pharmacological Properties: Grastim acts as a G-CSF analog, stimulating the bone marrow to produce more neutrophils, thereby enhancing the body’s immune response.
Indications for Use
Indications: Grastim Solution for Injections is indicated for the treatment of neutropenia, particularly in patients undergoing chemotherapy, where there is a low level of white blood cells.
Contraindications
Contraindications: Do not use Grastim Solution for Injections if you are allergic to any of the ingredients. Consult a healthcare provider before starting this medication.
Side Effects
Side Effects: Common side effects may include bone pain, headache, fatigue, and injection site reactions. Contact your healthcare provider if you experience severe side effects.
Usage Instructions
Usage: The recommended dosage and administration of Grastim Solution for Injections should be determined by a healthcare professional based on individual needs. It is typically administered as a subcutaneous injection.
Benefits Compared to Analogues
Benefits: Grastim has shown efficacy in reducing the incidence of febrile neutropenia in cancer patients undergoing chemotherapy, as demonstrated in clinical trials.
Suitable Patient Groups
Patient Groups: Grastim Solution for Injections is suitable for adults and children requiring treatment for neutropenia. Dosage adjustments may be necessary based on individual patient characteristics.
Storage and Shelf Life
Storage: Store Grastim Solution for Injections as directed on the packaging. Do not use beyond the expiration date indicated on the product. Keep it out of reach of children.
Packaging Description
Packaging: Each package contains a 1ml syringe of Grastim Solution for Injections, providing a convenient and sterile delivery method for administration.
Clinical Evidence and Effectiveness
Clinical Studies: Research published in the Journal of Clinical Oncology demonstrated that Grastim significantly reduced the incidence of febrile neutropenia in cancer patients undergoing chemotherapy. Another study published in the European Journal of Cancer showed a decrease in infection risk and hospitalization duration in patients with solid tumors.
